Kimia biosciences Limited has successfully concluded its board meeting held on February 14, 2026, approving key corporate decisions including quarterly financial results and executive leadership continuity. The pharmaceutical company's board meeting, conducted at the corporate office in New Delhi, addressed critical business matters requiring director approval.

Board Meeting Outcomes

The board meeting, which commenced at 01:00 PM and concluded at 02:00 PM, resulted in several important approvals:

Managing Director Re-appointment Approved

The board approved the re-appointment of Mr. Sameer Goel (DIN: 00161786) as Managing Director for a further period of five years. The 52-year-old Delhi University Commerce graduate brings extensive experience in the Indian API market with strong capabilities in business development, product development, strategic marketing, and operations management. His re-appointment is effective from February 14, 2026, subject to shareholder approval.

Postal Ballot and Additional Appointments

The board approved a postal ballot notice to seek shareholder approval for two key matters. The company appointed Mr. Maghisuddin (Membership No: 51216, COP No: 27850), Proprietor of M/s M & Company, as scrutinizer to oversee the postal ballot e-voting process.

Committee Re-constitution

Following the induction of Mr. Kaku Vijaya Shekhar Reddy as Additional Director in the category of Whole Time Director, the board re-constituted its committees. The Nomination and Remuneration Committee and Stakeholders Relationship Committee now include Jagdeep Dhawan as Chairman, Kaku Vijaya Shekhar Reddy as Member, and Richa Gupta as Member. The Corporate Social Responsibility Committee comprises Sameer Goel as Chairman, Jagdeep Dhawan as Member, and Kaku Vijaya Shekhar Reddy as Member.

The company maintains its registered office and manufacturing works at Village Bhondsi, Damdama Lake Road, Gurugram, Haryana, with corporate office operations from Aggarwal Millennium Tower-II in Netaji Subhash Place, Pitampura, New Delhi. Company Secretary and Compliance Officer Pallavi Garg executed the regulatory filings in compliance with SEBI listing obligations.

Kimia biosciences Limited has secured a significant patent grant from The Patent Office, Government of India, strengthening its position in the antifungal pharmaceutical segment. The company announced this development through a regulatory filing to BSE Limited on February 10, 2026, pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Patent Details and Specifications

The patent, officially numbered 579384, covers an "Improved Process for the Preparation of Luliconazole," an important antifungal active pharmaceutical ingredient (API). The patent certificate confirms the grant for a standard term of 20 years, effective from the original filing date.

Strategic Impact on Business Portfolio

The patent grant represents a significant addition to Kimia Biosciences' intellectual property portfolio, particularly in the antifungal API segment. According to the company's regulatory communication, this patent is expected to enhance long-term business prospects by providing exclusive rights to the improved manufacturing process for Luliconazole.

Luliconazole is a topical antifungal medication used to treat various fungal skin infections. The patent covers an improved preparation process, which could potentially offer manufacturing advantages such as enhanced efficiency, better yield, or improved product quality compared to existing methods.

Regulatory Compliance and Documentation

The announcement was made through proper regulatory channels, with Company Secretary and Compliance Officer Pallavi Garg (Membership No. A69848) signing the disclosure document. The filing includes the complete patent certificate as supporting documentation, ensuring full transparency with stakeholders and regulatory authorities.

Patent Maintenance Requirements

The patent certificate specifies that renewal fees for maintaining the patent will be due on January 9, 2024, and annually thereafter on the same date. This ongoing financial commitment will be necessary to preserve the exclusive rights throughout the 20-year patent term.

This patent grant positions Kimia Biosciences Limited to potentially leverage its proprietary process technology in the competitive antifungal API market, providing a foundation for future business development and market expansion opportunities.